Volume 7.01 | Jan 15

Mammary Cell News 7.01 January 15, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
BCL11A Is a Triple-Negative Breast Cancer Gene with Critical Functions in Stem and Progenitor Cells
Researchers report that the transcription factor ​BCL11A is overexpressed in triple-negative breast cancer (TNBC) including basal-like breast cancer (BLBC) and that its genomic locus is amplified in up to 38% of BLBC tumors. Exogenous ​BCL11A overexpression promotes tumor formation, whereas its knockdown in TNBC cell lines suppresses their tumorigenic potential in xenograft models. [Nat Commun] Full Article | Press Release
Request a Sample: ReproTeSR™
PUBLICATIONS (Ranked by impact factor of the journal)

Interferon Regulatory Factor-1 Signaling Regulates the Switch between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate
Investigators report an inverse correlation in expression of nuclear interferon regulatory factor-1 and the autophagy regulator ATG7 in human breast cancer cells that directly impacts their cell fate. [Cancer Res] Abstract | Full Article

Stem-Cell-Like Properties and Epithelial Plasticity Arise as Stable Traits after Transient Twist1 Activation
The authors show that Twist1 activation primes a subset of mammary epithelial cells for stem-cell-like properties, which only emerge and stably persist following Twist1 deactivation. [Cell Rep]
Full Article | Graphical Abstract

BRCA1-IRIS Inactivation Overcomes Paclitaxel Resistance in Triple Negative Breast Cancers
Researchers investigated the role of BRCA1-IRIS as a novel treatment target for triple negative breast cancers (TNBC) and their paclitaxel-resistant recurrences. They analyzed the response of BRCA1-IRIS overexpressing normal mammary cells or established TNBC cells silenced from BRCA1-IRIS to paclitaxel in vitro and in vivo. [Breast Cancer Res] Abstract | Full Article

A Co-Culture Genome-Wide RNAi Screen with Mammary Epithelial Cells Reveals Transmembrane Signals Required for Growth and Differentiation
Investigators developed and utilized a cytogenetically normal clonal line of hTERT immortalized human mammary epithelial cells in a fibroblast-enhanced co-culture assay to conduct a genome-wide siRNA screen evaluating the functional effect of silencing each gene. [Breast Cancer Res] Abstract | Full Article

Autophagy Supports Breast Cancer Stem Cell Maintenance by Regulating IL6 Secretion
Inhibition of autophagy by knockdown of ATG7 or BECN1 modified the CD44+/CD24low/- population in breast cancer cells by regulating CD24 and IL6 secretion. [Mol Cancer Res] Abstract

EMT Transition Alters Interstitial Fluid Flow-Induced Signaling in ERBB2-Positive Breast Cancer Cells
Scientists identified a novel signaling mechanism for interstitial flow-induced invasion of ERBB2 expressing breast cancer cells, one that depends on epithelial-to-mesenchymal transition (EMT) and acts through a CXCR4/PI3K pathway. [Mol Cancer Res] Abstract

Araguspongine C Induces Autophagic Death in Breast Cancer Cells through Suppression of c-Met and HER2 Receptor Tyrosine Kinase Signaling
The authors evaluated the anticancer activity of the known oxaquinolizidine alkaloids araguspongines A, C, K and L, and xestospongin B against breast cancer cells. Araguspongine C inhibited the proliferation of multiple breast cancer cell lines in vitro in a dose-dependent manner. [Mar Drugs] Full Article

Overexpression of VEGF183 Promotes Murine Breast Cancer Cell Proliferation In Vitro and Induces Dilated Intratumoral Microvessels
To investigate the role of vascular endothelial growth factor (VEGF)183 in carcinogenesis, scientists generated murine breast cancer cell clones stably overexpressing VEGF183, VEGF121, VEGF165, and VEGF189. [Tumor Biol] Abstract


Preoperative Carboplatin-Paclitaxel-Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study
Investigators evaluated preoperative carboplatin-paclitaxel in combination with bevacizumab in triple-negative breast cancer patients with previously untreated stage II-III disease. [Ann Surg Oncol] Abstract

Phase III Placebo-Controlled, Double-Blind, Randomized Trial of Pegfilgrastim to Reduce the Risk of Febrile Neutropenia in Breast Cancer Patients Receiving Docetaxel/Cyclophosphamide Chemotherapy
Researchers conducted a double-blind, placebo-controlled, randomized trial to determine the efficacy of pegfilgrastim in reducing the risk of febrile neutropenia in early-stage breast cancer patients. [Support Care Cancer] Abstract

MammoCult™: Most Published Mammosphere & Tumorsphere Culture Medium (Commercially Available) FREE Sample Request
Targeting HER2 for the Treatment of Breast Cancer
Treatment with the anti-HER2 monoclonal antibody trastuzumab has revolutionized the outcome of patients with this aggressive breast cancer subtype, but intrinsic and acquired resistance is common. Growing understanding of the biology and complexity of the HER2 signaling network and of potential resistance mechanisms has guided the development of new HER2-targeted agents. [Annu Rev Med] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
OncoSec Medical Plans to Initiate Pilot Study in Triple Negative Breast Cancer
OncoSec Medical Inc. plans to initiate a pilot study to assess IL-12 ImmunoPulse in patients with triple negative breast cancer (TNBC). This pilot study is designed to assess whether IL-12 ImmunoPulse increases TNBC tumor immunogenicity by driving a pro-inflammatory cascade of events that leads to increases in cytotoxic tumor-infiltrating lymphocytes. [OncoSec Medical Inc.] Press Release

Positive Phase I Immune Responses in All Evaluable Ovarian and Breast Cancer Patients Advances Vaccine to Phase II Clinical Trials
TapImmune Inc. reports the completion of data analysis from all 21 evaluable patients treated in a Phase I clinical trial. Results indicate safety and positive immune response data in folate receptor alpha vaccine for ovarian and breast cancers. [TapImmune Inc.] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells?
Watch a video to see how ALDEFLUOR™ can help.
Nature Owner Merges with Publishing Giant
Consolidation is afoot in scientific publishing. Macmillan Science and Education, the London-based publisher of Nature and Scientific American, will merge with Berlin-based Springer Science+Business Media, one of the world’s largest science publishers. [Nature News] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW CIRM 2.0 Free Webinar – Changing the Way We Work
January 21, 2015 12:00 PM PST

NEW Gordon Research Conference: Stem Cells & Cancer
February 15-20, 2015
Ventura, United States

NEW 4th International Conference on Immunochemotherapy
April 16-17, 2015
Philadelphia, United States

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Positions – Cancer Bioengineering and Cancer Biology (University of Minnesota)

NEW Director of Research (Dr. Susan Love Research Foundation)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

Principal Investigator – Human Cancer Genomics and Mouse Modeling (Lunenfeld-Tanenbaum Research Institute)

Lab Manager – Precision Cancer Medicine (Boston University)

Postdoctoral Position – Precision Cancer Medicine (Boston University)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

Postdoctoral Position – Experimental Breast Cancer Therapy (University of Pennsylvania)

Postdoctoral Position – Breast Cancer Metastasis (Northwestern University)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Media Development (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us